Positive clinical trial results are a strong indicator of a company's progress and potential for future success, especially in the biopharmaceutical industry. These results can lead to increased investor optimism about the company's prospects, driving up the stock price in the short term. Given that the news is directly about Icosavax's primary product in development, it is highly relevant and important to the company's valuation.